Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7L27

Crystal structure of the catalytic domain of human PDE3A

Summary for 7L27
Entry DOI10.2210/pdb7l27/pdb
DescriptorcGMP-inhibited 3',5'-cyclic phosphodiesterase A, MANGANESE (II) ION, MAGNESIUM ION, ... (6 entities in total)
Functional Keywordshydrolase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains4
Total formula weight173269.71
Authors
Horner, S.W.,Garvie, C. (deposition date: 2020-12-16, release date: 2021-06-16, Last modification date: 2023-10-18)
Primary citationGarvie, C.W.,Wu, X.,Papanastasiou, M.,Lee, S.,Fuller, J.,Schnitzler, G.R.,Horner, S.W.,Baker, A.,Zhang, T.,Mullahoo, J.P.,Westlake, L.,Hoyt, S.H.,Toetzl, M.,Ranaghan, M.J.,de Waal, L.,McGaunn, J.,Kaplan, B.,Piccioni, F.,Yang, X.,Lange, M.,Tersteegen, A.,Raymond, D.,Lewis, T.A.,Carr, S.A.,Cherniack, A.D.,Lemke, C.T.,Meyerson, M.,Greulich, H.
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.
Nat Commun, 12:4375-4375, 2021
Cited by
PubMed Abstract: DNMDP and related compounds, or velcrins, induce complex formation between the phosphodiesterase PDE3A and the SLFN12 protein, leading to a cytotoxic response in cancer cells that express elevated levels of both proteins. The mechanisms by which velcrins induce complex formation, and how the PDE3A-SLFN12 complex causes cancer cell death, are not fully understood. Here, we show that PDE3A and SLFN12 form a heterotetramer stabilized by binding of DNMDP. Interactions between the C-terminal alpha helix of SLFN12 and residues near the active site of PDE3A are required for complex formation, and are further stabilized by interactions between SLFN12 and DNMDP. Moreover, we demonstrate that SLFN12 is an RNase, that PDE3A binding increases SLFN12 RNase activity, and that SLFN12 RNase activity is required for DNMDP response. This new mechanistic understanding will facilitate development of velcrin compounds into new cancer therapies.
PubMed: 34272366
DOI: 10.1038/s41467-021-24495-w
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon